Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: A guide to appropriate antimicrobial therapy

International Journal of Antimicrobial Agents

Volumn 22, Issue 4, 2003, Pages 406-419

  Jones, Mark E ^a   Karlowsky, James A ^b   Draghi, Deborah C ^b   Thornsberry, Clyde ^b   Sahm, Daniel F ^b   Nathwani, Dilip ^c  

^a Focus Technologies   (Netherlands)

^b Focus Technologies Incorporated   (United States)

^c NHS TAYSIDE   (United Kingdom)

Author keywords

Antimicrobial resistance; Skin soft tissue infection; Surveillance

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; BETA LACTAMASE; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; ERYTHROMYCIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MACROLIDE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; CITROBACTER; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; CROSS RESISTANCE; DRUG SCREENING; DRUG SENSITIVITY; EMPIRICISM; ENTEROBACTER; ENTEROCOCCUS; ESCHERICHIA COLI; EUROPE; FRANCE; GEOGRAPHIC DISTRIBUTION; GERMANY; HUMAN; HUMAN CELL; HUMAN TISSUE; ITALY; KLEBSIELLA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; OUTPATIENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEUS; PSEUDOMONAS AERUGINOSA; SKIN INFECTION; SOFT TISSUE INFECTION; SPAIN; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PYOGENES; TREATMENT PLANNING; UNITED STATES;

EID: 0141569273     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(03)00154-7     Document Type: Article

References (28)

1. Nathwani D., Moitra S., Dunbar J., Crosby G., Peterkin G., Davey P. Skin and soft tissue infections: development of a collaborative management plan between community and hospital care. Int. J. Clin. Pract. 52:1998;456-460.
2. Tice A.D. Experience with a physician-directed, clinic-based program for outpatient parenteral antibiotic therapy in the USA. Eur. J. Clin. Microbiol. Infect. Dis. 14:1995;655-661.
3. Dykhuizen R.S., Trent R.J., Pacitti D.P., Reid T.M., Douglas J.G., Smith C.C. An analysis of 900 consecutive admissions to a regional infection unit. J. Infect. 29:1994;189-193.
4. Forbes B.A., Sahm D.F., Weissfeld A.S. Diagnostic microbiology, skin soft tissue and wound infections. 11th ed:1998;972-984 Mosby, St. Louis, MO, USA. Chapter 63.
5. Bannister B.A., Begg N.T., Gillespie S.H. Infectious disease, skin, mucosal and soft tissue infections. 1996;76-102 Blackwell Science, Oxford, UK. Chapter 5.
6. Finch R. Skin and soft-tissue infections. Lancet. 23:1988;164-168.
7. Hook E.W. III, Hooton T.M., Horton C.A., Coyle M.B., Ramsey P.G., Turck M. Microbiologic evaluation of cutaneous cellulitis in adults. Arch. Intern. Med. 146:1986;95-97.
8. Fleisher G., Ludwig S., Campos J. Cellulitis: bacterial etiology, clinical features and laboratory findings. J. Pediatr. Dis. 97:1980;591-593.
9. Jones M.E., Schmitz F.J., Fluit A.C., Acar J., Gupta R., Verhoef J. Frequency of occurrence and antimicrobial susceptibility of bacterial pathogens associated with skin and soft tissue infections during 1997 from an International Surveillance Programme. SENTRY Participants Group. Eur. J. Clin. Microbiol. Infect. Dis. 18:1999;403-408.
10. Doern G.V., Jones R.N., Pfaller M.A., Kugler K.C., Beach M.L. Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). SENTRY Study Group (North America). Diagn. Microbiol. Infect. Dis. 37:1999;65-72.
11. Anonymous. Surveillance of surgical site infections. Communicable diseases weekly report, vol. 10. London UK: Public Health Laboratory Service. 31 January 2000.
12. Kaul R., McGeer A., Low D.E., Green K., Schwartz B. Population-based surveillance for group A streptococcal necrotising fasciitis: clinical features, prognostic indicators, and microbiologic analysis of 77 cases. Ontario Group A Streptococcal Study. Am. J. Med. 103:1997;18-24.
13. Sahm D.F., Marsilio M.K., Piazza G. Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with the surveillance network database - USA. Clin. Infect. Dis. 29:1999;259-263.
14. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial tests for bacteria that grow aerobically; 5th edition. NCCLS document M7-A5. Wayne, PA, 2000.
15. Comité de L' Antibiogramme De La Societé Française de Microbiologie Communiqué 2000-2001 (edition Janvier 2001). Société Française de Microbiologie, Institut Pasteur, 28, rue du Dr Roux, F 75724 Paris Cedex 15, France, 2001.
16. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Eleventh informational supplement. NCCLS document M100-S11. Wayne, PA, USA, 2001.
17. Hadziyannis E., Tuohy M., Thomas L., Procop G.W., Washington J.A., Hal G.S. Screening and confirmatory testing for extended spectrum β-lactamases (ESBL) in Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca clinical isolates. Diagn. Microbiol. Infect. Dis. 36:2000;113-117.
18. Schachner L., Taplin D., Scott G.B., Morrison M. A therapeutic update of superficial skin infections. Pediatr. Clin. North Am. 30:1983;397-404.
19. File T.M. Jr, Tan J.S. Treatment of skin and soft-tissue infections. Am. J. Surg. 169:(5A Suppl.):1995;27S-33S.
20. Nathwani D., Davey P. Intravenous antimicrobial chemotherapy in the community: underused inadequately resourced, or irrelevant to healthcare in Britain. Br. Med. J. 313:1996;1541-1543.
21. Broadhurst L.E., Erickson R.L., Kelley P.W. Decreases in invasive Haemophilus influenzae diseases in US army children, 1984 through 1991. J. Am. Med. Assoc. 13:1993;227-231.
22. Abrahamain F.M. Dog bites: bacteriology, management, and prevention. Curr. Infect. Dis. Rep. 2:2000;446-453.
23. Giacometti A., Cirioni O., Schimizzi A.M., et al. Epidemiology and microbiology of surgical wound infections. J. Clin. Microbiol. 38:2000;918-922.
24. Vinken A., Li Z., Balan D., Rittenhouse B., Willke R., Nathwani D. Economic evaluation of linezolidzzzz, flucloxacillin and vancomycin in the empirical treatment of cellulitis in UK hospitals: a decision analytical model. J. Hosp. Infect. 49:(Suppl. A):2001;S13-S24.
25. Eron L.J., Park C.H., Hixon D.L., Goldenberg R.I., Poretz D.M. Ceftriaxone therapy of bone and soft tissue infections in hospital and outpatient settings. Antimicrob. Agent Chemother. 23:1983;731-737.
26. Nathwani D., Tice A. Ambulatory antimicrobial use: the value of an outcome registry. J. Antimicrob. Chemother. 49:2002;149-154.
27. Doern G.V., Ferraro M.J., Brueggemann A.B., Ruoff K.L. Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Antimicrob. Agent Chemother. 40:1996;891-894.
28. Gustafson T.L., Band J.D., Hutcheson R.H. Jr, Schaffner W. Pseudomonas folliculitis: an outbreak and review. Rev. Infect. Dis. 5:1983;1-8.